Cat Spire (cat allergy T-cell vaccine)fails in phase III study.- Circassia Pharma.
Circassia Pharmaceuticals plc announced top-line results from its investigational cat allergy immunotherapy phase III study. In the study, both treatment regimens and placebo greatly, and equally, reduced subjects� combined allergy symptom and rescue medication use score from baseline. As a result of the very marked placebo effect the treatment did not meet the study�s primary endpoint. The treatment was well tolerated with a highly favourable safety profile.
Circassia will now review the study�s full dataset to understand the detailed results and assess whether any other confounding factors affected the outcome, as well as the implications for its allergy portfolio. In the meantime, the Company will stop the recently initiated registration study of its grass allergy treatment and the preparatory work for a dose-ranging study of its ragweed allergy therapy. The phase IIb study of Circassia�s house dust mite allergy product is well advanced and the Company will assess the implications associated with continuing the trial. Circassia�s birch allergy product is nearing completion of a phase II study, which will therefore continue.
Related news and insights
Zai Lab Limited and its partner Entasis Therapeutics Holdings Inc. announced topline results from the ATTACK trial, a global Phase III registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii.
Atea Pharmaceuticals, Inc. reported that the global Phase II MOONSONG trial evaluating AT 527 in the outpatient setting did not meet the primary endpoint of reduction from baseline in the amount of SARS-CoV-2 virus in patients with mild or moderate COVID-19 compared to placebo in the overall study population, of which approximately two thirds of patients were low-risk with mild symptoms.